Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fluindione is a small molecule oral anticoagulant belonging to the class of vitamin K antagonists (VKAs). It acts by inhibiting the vitamin K cycle, thereby reducing the synthesis of vitamin K-dependent clotting factors in the liver, which are essential for blood coagulation. This mechanism helps prevent blood clots from forming or growing larger. Fluindione is primarily used for the treatment and prevention of venous thrombosis, pulmonary embolism, atrial fibrillation (to reduce stroke risk), and other thromboembolic disorders requiring long-term anticoagulation. It is most widely used in France as an alternative to warfarin and is marketed under the brand name Previscan[1][2][3][4][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fluindione.